New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)Adds significant manufacturing capacity
/PRNewswire/ Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), today announced its consolidated results for the third quarter (Q3) and nine month (9M).
The Board of Directors of Piramal Pharma Limited, at its meeting held today have approved the financial results of the company for the period ended December 31, 2022 - Q3FY23 and 9MFY23.
MUMBAI, India, Feb. 8, 2023 /PRNewswire/ Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), today announced its consolidated results for the third quarter (Q3) and nine month (9M) ended
/PRNewswire/ Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), today announced its consolidated results for the third quarter (Q3) and nine month (9M).